Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2

作者：Gilgen Nicole; Farah Ahmed; Scheller Bruno; Ohlow Marc Alexander; Mangner Norman; Weilenmann Daniel; Woehrle Jochen; Jamshidi Peiman; Leibundgut Gregor; Moebius Winkler Sven; Zweiker Robert; Krackhardt Florian; Butter Christian; Bruch Leonhard; Kaiser Christoph; Hoffmann Andreas; Rickenbacher Peter; Mueller Christian; Stephan Frank Peter; Coslovsky Michael; Jeger Raban^*

来源：Clinical Cardiology, 2018, 41(5): 569-575.

DOI：10.1002/clc.22942

• Angioplasty
• Coronary Artery Disease
• Drug-Coated Balloon
• Randomized Controlled Trial
• Small Coronary Vessel
• Trial Design

The treatment of coronary small vessel disease (SVD) remains an unresolved issue. Drug-eluting stents (DES) have limited efficacy due to increased rates of instent-restenosis, mainly caused by late lumen loss. Drug-coated balloons (DCB) are a promising technique because native vessels remain structurally unchanged. Basel Stent Kosten-Effektivitats Trial: Drug-Coated Balloons vs. Drug-Eluting Stents in Small Vessel Interventions (BASKET-SMALL 2) is a multicenter, randomized, controlled, noninferiority trial of DCB vs DES in native SVD for clinical endpoints. Seven hundred fifty-eight patients with de novo lesions in vessels <3mm in diameter and an indication for percutaneous coronary intervention such as stable angina pectoris, silent ischemia, or acute coronary syndromes are randomized 1:1 to angioplasty with DCB vs implantation of a DES after successful initial balloon angioplasty. The primary endpoint is the combination of cardiac death, nonfatal myocardial infarction, and target-vessel revascularization up to 1year. Secondary endpoints include stent thrombosis, Bleeding Academic Research Consortium (BARC) type 3 to 5 bleeding, and long-term outcome up to 3years. Based on clinical endpoints after 1year, we plan to assess the noninferiority of DCB compared to DES in patients undergoing primary percutaneous coronary intervention for SVD. Results will be available in the second half of 2018. This study will compare DCB and DES regarding long-term safety and efficacy for the treatment of SVD in a large all-comer population.

• 出版日期2018-5